Acura Pharmaceuticals to Present at the Cowen Health Care Conference on March 5, 2013

Acura Pharmaceuticals to Present at the Cowen Health Care Conference on March 
5, 2013 
PALATINE, IL -- (Marketwire) -- 02/22/13 --  Acura Pharmaceuticals,
Inc. (NASDAQ: ACUR), a specialty pharmaceutical company developing
products intended to address medication abuse and misuse, announced
today that the Company will present at the Cowen and Company Health
Care Conference at the Boston Marriott Copley Place on Tuesday, March
5, 2013. Bob Jones, Acura Pharmaceutical's Chief Executive Officer,
will provide a company update at 8:40AM Eastern Time. In advance of
this presentation the Company plans to report financial results for
the fourth quarter and fiscal year ended December 2012 following the
close of markets on Monday, March 4, 2013. 
A live webcast of the presentation will be available through the
"Investors" page of Acura's website: www.acurapharm.com. An archived
version of the presentation will be available for 30 days after the
event. 
About Acura Pharmaceuticals
 Acura Pharmaceuticals is a specialty
pharmaceutical company engaged in the research, development and
commercialization of product candidates intended to address
medication abuse and misuse, utilizing its proprietary AVERSION(R)
and IMPEDE(TM) technologies. AVERSION contains polymers that cause
the drug to gel when dissolved; it also contains compounds that
irritate the nasal passages. IMPEDE is designed to disrupt the
processing of pseudoephedrine from tablets into methamphetamine. 
In June 2011, the U.S. Food and Drug Administration approved
OXECTA(R) (oxycodone HC1 tablets) which incorporates the AVERSION(R)
technology. The Company has a development pipeline of additional
AVERSION(R) technology products containing other opioids.  
In December 2012, the Company commenced commercialization of
Nexafed(R) [pseudoephedrine hydrochloride (HCl)], a 30 mg
immediate-release abuse-deterrent decongestant. The next generation
pseudoephedrine tablet combines effective nasal congestion relief
with IMPEDE(TM) technology, a unique polymer matrix that disrupts the
conversion of pseudoephedrine into the dangerous drug,
methamphetamine.  
The trademark OXECTA(R) is owned by Pfizer Inc. 
Contact: 
for Acura Investor Relations
investors@acurapharm.com
847-705-7709 
for Acura Media Relations
pr@acurapharm.com
847-705-7709 
 
 
Press spacebar to pause and continue. Press esc to stop.